Coromandel International Ltd
Coromandel International Ltd is one of India's leading agri solutions provider. It offers a diverse range of products and services across the farming value chain. It specializes in fertilizers, crop protein, bio pesticide, specialty nutrients, organic fertilizers, etc.[1]
Revenue Breakup
The company's business is divided among 2 main segments i.e. nutrient and other allied products (~85% of revenues) and crop protection (~15% of revenues).[2]
Fertilizers Business
The company sells various types of phosphatic fertilizers in the domestic market. It has ~40% share in the unique grade fertilizer sales in India. Overall, it is the 2nd largest phosphatic seller in India and largest single super phosphate (SSP) seller with a market share of ~15%.[3] It has a leading position in the states of Andhra Pradesh and Telangana; India's largest complex-fertiliser markets.[4]
Crop Protection Business
Under this business, the company sells a wide range of crop protection products under its 60+ brands based portfolio. It is 3rd largest manufacturer of mancozeb globally and exports accounts for ~37% of revenues of the business.[5]
Biologicals Business
The company has a rich product pipeline with research on compounds from plant extracts and microbial bio-pesticides. It is a leading manufacturer of azadirachtin in the world with ~65% export share. It exports to USA, Canada and Europe.[6]
- Market Cap ₹ 52,373 Cr.
- Current Price ₹ 1,778
- High / Low ₹ 1,839 / 1,025
- Stock P/E 38.6
- Book Value ₹ 345
- Dividend Yield 0.34 %
- ROCE 26.0 %
- ROE 18.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.0%
- Company has been maintaining a healthy dividend payout of 17.1%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Fertilizers Industry: Fertilizers
Part of Nifty LargeMidcap 250 Nifty Total Market Nifty 500 Multicap 50:25:25 BSE 250 LargeMidCap Index Nifty Midcap 150
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9,034 | 10,053 | 11,306 | 11,481 | 10,031 | 11,083 | 13,225 | 13,137 | 14,182 | 19,111 | 29,628 | 22,058 | 21,539 | |
8,264 | 9,246 | 10,450 | 10,712 | 9,048 | 9,822 | 11,775 | 11,400 | 12,193 | 16,954 | 26,726 | 19,678 | 19,475 | |
Operating Profit | 770 | 808 | 856 | 769 | 983 | 1,261 | 1,450 | 1,737 | 1,989 | 2,156 | 2,902 | 2,380 | 2,064 |
OPM % | 9% | 8% | 8% | 7% | 10% | 11% | 11% | 13% | 14% | 11% | 10% | 11% | 10% |
68 | 46 | 50 | 87 | 54 | 55 | 8 | 35 | 76 | 141 | 171 | 223 | 261 | |
Interest | 210 | 240 | 210 | 221 | 224 | 178 | 251 | 235 | 106 | 75 | 190 | 187 | 223 |
Depreciation | 71 | 96 | 105 | 106 | 101 | 99 | 114 | 158 | 173 | 173 | 182 | 229 | 261 |
Profit before tax | 557 | 517 | 592 | 529 | 712 | 1,038 | 1,093 | 1,379 | 1,786 | 2,050 | 2,701 | 2,188 | 1,841 |
Tax % | 22% | 29% | 32% | 32% | 33% | 33% | 34% | 23% | 26% | 25% | 25% | 25% | |
434 | 365 | 402 | 357 | 477 | 691 | 720 | 1,065 | 1,329 | 1,528 | 2,013 | 1,641 | 1,360 | |
EPS in Rs | 15.26 | 12.59 | 13.80 | 12.27 | 16.35 | 23.64 | 24.63 | 36.36 | 45.30 | 52.08 | 68.46 | 55.78 | 46.41 |
Dividend Payout % | 29% | 36% | 33% | 33% | 31% | 27% | 26% | 33% | 26% | 23% | 18% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 11% |
3 Years: | 16% |
TTM: | -19% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 17% |
3 Years: | 7% |
TTM: | -33% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | 28% |
3 Years: | 34% |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 25% |
3 Years: | 24% |
Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 28 | 28 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 |
Reserves | 2,168 | 2,253 | 2,173 | 2,605 | 2,862 | 2,867 | 3,329 | 4,288 | 5,121 | 6,329 | 7,878 | 9,390 | 10,126 |
2,946 | 1,843 | 2,288 | 2,677 | 2,228 | 2,728 | 2,954 | 2,019 | 385 | 395 | 393 | 492 | 580 | |
3,270 | 3,481 | 3,872 | 3,871 | 3,526 | 4,224 | 4,261 | 3,812 | 3,360 | 4,532 | 5,934 | 5,933 | 6,238 | |
Total Liabilities | 8,412 | 7,605 | 8,362 | 9,182 | 8,645 | 9,848 | 10,574 | 10,149 | 8,895 | 11,285 | 14,235 | 15,845 | 16,973 |
1,856 | 1,734 | 1,380 | 1,320 | 1,328 | 1,327 | 1,309 | 2,032 | 2,015 | 2,092 | 2,200 | 3,112 | 3,433 | |
CWIP | 420 | 74 | 46 | 42 | 22 | 48 | 191 | 65 | 90 | 141 | 399 | 235 | 162 |
Investments | 160 | 342 | 352 | 477 | 388 | 221 | 201 | 211 | 214 | 243 | 287 | 854 | 943 |
5,976 | 5,455 | 6,583 | 7,343 | 6,907 | 8,252 | 8,873 | 7,840 | 6,576 | 8,809 | 11,348 | 11,644 | 12,436 | |
Total Assets | 8,412 | 7,605 | 8,362 | 9,182 | 8,645 | 9,848 | 10,574 | 10,149 | 8,895 | 11,285 | 14,235 | 15,845 | 16,973 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
985 | 1,461 | 86 | 18 | 915 | 263 | 526 | 1,862 | 4,150 | 2,078 | 591 | 1,428 | |
-640 | -81 | -216 | -61 | -79 | 38 | -597 | -220 | -1,245 | -1,622 | 640 | -1,333 | |
-929 | -1,344 | -64 | 8 | -864 | -1 | -244 | -1,723 | -2,263 | -443 | -543 | -363 | |
Net Cash Flow | -583 | 35 | -194 | -34 | -28 | 300 | -314 | -82 | 642 | 14 | 688 | -269 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 74 | 54 | 47 | 52 | 59 | 52 | 50 | 48 | 14 | 5 | 7 | 23 |
Inventory Days | 79 | 86 | 96 | 98 | 88 | 109 | 127 | 109 | 98 | 94 | 69 | 102 |
Days Payable | 129 | 132 | 131 | 135 | 150 | 162 | 147 | 135 | 110 | 100 | 83 | 119 |
Cash Conversion Cycle | 24 | 7 | 12 | 15 | -3 | -2 | 30 | 22 | 2 | -1 | -7 | 6 |
Working Capital Days | 94 | 55 | 77 | 106 | 121 | 116 | 123 | 111 | 65 | 41 | 37 | 47 |
ROCE % | 14% | 16% | 19% | 15% | 18% | 23% | 23% | 26% | 32% | 35% | 38% | 26% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
2d - Intimation of lost share certificates by shareholders.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Dec - Investor & Analyst Meet scheduled on December 16, 2024.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
9 Dec - Dispatch of confirmation letters for lost share certificates.
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 6 Dec
-
Disclosure Under Regulations 30 Of SEBI (LODR) Regulations, 2015
29 Nov - Disclosure regarding customs order and IGST exemption.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jul 2021TranscriptPPT
-
Apr 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptNotesPPT
-
Jul 2019TranscriptPPT
-
Apr 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Aug 2018TranscriptNotesPPT
-
Jul 2018TranscriptPPT
-
Jun 2018TranscriptNotesPPT
-
Apr 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Nov 2017Transcript PPT
-
Jul 2017TranscriptPPT
-
Apr 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Nov 2016Transcript PPT
-
Jul 2016TranscriptPPT
-
Apr 2016TranscriptPPT
-
Jan 2016TranscriptPPT
Business Segments
1) Crop Nutrition (89% in Q1 FY25 vs 87% in FY22): [1] [2] This segment includes products like: